Juvenile Animal Toxicity Studies of Pharmaceuticals and Industrial Chemicals for Regulatory Preclinical Safety Assessment

Juvenile Animal toxicity Studies (JAS) are conducted to evaluate potential safety risks, particularly those affecting postnatal growth and development, that may not be detectable through standard toxicity studies or pediatric clinical trials. These studies play a crucial role in identifying developmental toxicities and supporting the safe inclusion of children in clinical research. Unlike traditional reproductive and developmental toxicity tests, JAS are not guided by rigid regulatory frameworks and are designed on a case-by-case basis. To address this, regulatory agencies such as the ICH, FDA, and EMA have introduced guidelines to support the appropriate planning and execution of these studies. Specifically, ICH M3(R2) and the recently finalized ICH S11 provide harmonized standards for nonclinical safety testing in pediatric drug development, emphasizing flexibility based on the drug’s characteristics and target population. Key considerations in designing JAS include the drug’s intended use, target pediatric age group, treatment duration, and species-specific differences in pharmacokinetics and toxicity. Special attention is required when the drug may impact developing organ systems like the kidneys, bones, or central nervous system. The relevance and reliability of JAS findings largely depend on appropriate species selection and treatment timing within the developmental window. In the context of regulatory preclinical safety assessment, both pharmaceuticals and industrial chemicals must undergo rigorous toxicological evaluation to ensure safety, particularly for vulnerable populations such as children. For pharmaceuticals, JAS provide critical data for pediatric risk assessment and support clinical trial design. For industrial chemicals, regulatory agencies such as the EPA (Environmental Protection Agency) and ECHA (European Chemicals Agency) may require juvenile toxicity data under programs like REACH (Registration, Evaluation, Authorisation, and Restriction of Chemicals), particularly when there is potential for pediatric exposure. In both sectors, developmental toxicity studies are essential for characterizing age-specific hazards, determining safe exposure levels, and informing labeling and risk mitigation strategies.